|
1.
|
Richardson PG, Barlogie B, Berenson J, et
al: A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Moreau P, Richardson PG, Cavo M, Orlowski
RZ, San Miguel JF, Palumbo A and Harousseau JL: Proteasome
inhibitors in multiple myeloma: 10 years later. Blood. 120:947–959.
2012.PubMed/NCBI
|
|
3.
|
Anderson KC: New insights into therapeutic
targets in myeloma. Hematology Am Soc Hematol Educ Program.
2011:184–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bird JM, Owen RG, D’Sa S, et al:
Guidelines for the diagnosis and management of multiple myeloma
2011. Br J Haematol. 154:32–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Laubach J, Richardson P and Anderson K:
Multiple myeloma. Annu Rev Med. 62:249–264. 2011. View Article : Google Scholar
|
|
6.
|
Feinman R, Siegel DS and Berenson J:
Regulation of NF-kB in multiple myeloma: therapeutic implications.
Clin Adv Hematol Oncol. 2:162–166. 2004.PubMed/NCBI
|
|
7.
|
Li ZW, Chen H, Campbell RA, Bonavida B and
Berenson JR: NF-kappaB in the pathogenesis and treatment of
multiple myeloma. Curr Opin Hematol. 15:391–399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hideshima T, Chauhan D, Richardson P, et
al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol
Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chauhan D, Hideshima T, Mitsiades C,
Richardson P and Anderson KC: Proteasome inhibitor therapy in
multiple myeloma. Mol Cancer Ther. 4:686–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kawaguchi T, Miyazawa K, Moriya S, et al:
Combined treatment with bortezomib plus bafilomycin A1 enhances the
cytocidal effect and induces endoplasmic reticulum stress in U266
myeloma cells: crosstalk among proteasome, autophagy-lysosome and
ER stress. Int J Oncol. 38:643–654. 2011.
|
|
11.
|
Hideshima T, Ikeda H, Chauhan D, et al:
Bortezomib induces canonical nuclear factor-kappaB activation in
multiple myeloma cells. Blood. 114:1046–1052. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Li C, Chen S, Yue P, Deng X, Lonial S,
Khuri FR and Sun SY: Proteasome inhibitor PS-341 (bortezomib)
induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem.
285:16096–16104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Jia L, Gopinathan G, Sukumar JT and
Gribben JG: Blocking autophagy prevents bortezomib-induced
NF-kappaB activation by reducing I-kappaBalpha degradation in
lymphoma cells. PLoS One. 7:e325842012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Conticello C, Giuffrida R, Adamo L, et al:
NF-kappaB localization in multiple myeloma plasma cells and
mesenchymal cells. Leuk Res. 35:52–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Obeng EA, Carlson LM, Gutman DM,
Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce
a terminal unfolded protein response in multiple myeloma cells.
Blood. 107:4907–4916. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Meister S, Schubert U, Neubert K, et al:
Extensive immunoglobulin production sensitizes myeloma cells for
proteasome inhibition. Cancer Res. 67:1783–1792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Periyasamy Thandavan S, Jackson WH,
Samaddar JS, et al: Bortezomib blocks the catabolic process of
autophagy via a cathepsin-dependent mechanism, affects endoplasmic
reticulum stress and induces caspase-dependent cell death in
antiestrogen-sensitive and resistant ER+ breast cancer
cells. Autophagy. 6:19–35. 2010.
|
|
18.
|
Fels DR, Ye J, Segan AT, et al:
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells
via overactivation of endoplasmic reticulum stress pathways. Cancer
Res. 68:9323–9330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ri M, Iida S, Nakashima T, et al:
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5
in preventing the accumulation of unfolded proteins and fatal ER
stress. Leukemia. 24:1506–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ron D and Walter P: Signal integration in
the endoplasmic reticulum unfolded protein response. Nat Rev Mol
Cell Biol. 8:519–529. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Herr I and Debatin KM: Cellular stress
response and apoptosis in cancer therapy. Blood. 98:2603–2614.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Verfaillie T, Salazar M, Velasco G and
Agostinis P: Linking ER stress to autophagy: potential implications
for cancer therapy. Int J Cell Biol. 2010:9305092010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Mizushima N and Levine B: Autophagy in
mammalian development and differentiation. Nat Cell Biol.
12:823–830. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Janku F, McConkey DJ, Hong DS and Kurzrock
R: Autophagy as a target for anticancer therapy. Nat Rev Clin
Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kirkin V, McEwan DG, Novak I and Dikic I:
A role for ubiquitin in selective autophagy. Mol Cell. 34:259–269.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Korolchuk VI, Menzies FM and Rubinsztein
DC: Mechanisms of cross-talk between the ubiquitin-proteasome and
autophagylysosome systems. FEBS Lett. 584:1393–1398. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Nakamura M, Kikukawa Y, Takeya M, Mitsuya
H and Hata H: Clarithromycin attenuates autophagy in myeloma cells.
Int J Oncol. 37:815–820. 2010.PubMed/NCBI
|
|
29.
|
Renna M, Schaffner C, Brown K, et al:
Azithromycin blocks autophagy and may predispose cystic fibrosis
patients to mycobacterial infection. J Clin Invest. 121:3554–3563.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Moriya S, Miyazawa K, Kawaguchi T, Che XF
and Tomoda A: Involvement of endoplasmic reticulum stress-mediated
CHOP (GADD153) induction in the cytotoxicity of
2-aminophenoxazine-3-one in cancer cells. Int J Oncol. 39:981–988.
2011.PubMed/NCBI
|
|
31.
|
Shen D, Coleman J, Chan E, Nicholson TP,
Dai L, Sheppard PW and Patton WF: Novel cell- and tissue-based
assays for detecting misfolded and aggregated protein accumulation
within aggresomes and inclusion bodies. Cell Biochem Biophys.
60:173–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Klionsky DJ, Abdalla FC, Abeliovich H, et
al: Guidelines for the use and interpretation of assays for
monitoring autophagy. Autophagy. 8:445–544. 2012. View Article : Google Scholar
|
|
33.
|
Komatsu S, Miyazawa K, Moriya S, et al:
Clarithromycin enhances bortezomib-induced cytotoxicity via
endoplasmic reticulum stress-mediated CHOP (GADD153) induction and
autophagy in breast cancer cells. Int J Oncol. 40:1029–1039.
2012.
|
|
34.
|
Nawrocki ST, Carew JS, Maclean KH, et al:
Myc regulates aggresome formation, the induction of Noxa, and
apoptosis in response to the combination of bortezomib and SAHA.
Blood. 112:2917–2926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Tabas I and Ron D: Integrating the
mechanisms of apoptosis induced by endoplasmic reticulum stress.
Nat Cell Biol. 13:184–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Bays NW, Gardner RG, Seelig LP, Joazeiro
CA and Hampton RY: Hrd1p/Der3p is a membrane-anchored ubiquitin
ligase required for ER-associated degradation. Nat Cell Biol.
3:24–29. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Tsai YC and Weissman AM: Ubiquitylation in
ERAD: reversing to go forward? PLoS Biol. 9:e10010382011.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Lee JY, Koga H, Kawaguchi Y, et al: HDAC6
controls auto-phagosome maturation essential for
ubiquitin-selective quality-control autophagy. EMBO J. 29:969–980.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Hideshima T, Bradner JE, Wong J, Chauhan
D, Richardson P, Schreiber SL and Anderson KC: Small-molecule
inhibition of proteasome and aggresome function induces synergistic
antitumor activity in multiple myeloma. Proc Natl Acad Sci USA.
102:8567–8572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Rodriguez Gonzalez A, Lin T, Ikeda AK,
Simms Waldrip T, Fu C and Sakamoto KM: Role of the aggresome
pathway in cancer: targeting histone deacetylase 6-dependent
protein degradation. Cancer Res. 68:2557–2560. 2008.PubMed/NCBI
|
|
41.
|
Milani M, Rzymski T, Mellor HR, Pike L,
Bottini A, Generali D and Harris AL: The role of ATF4 stabilization
and autophagy in resistance of breast cancer cells treated with
Bortezomib. Cancer Res. 69:4415–4423. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Rzymski T, Milani M, Singleton DC and
Harris AL: Role of ATF4 in regulation of autophagy and resistance
to drugs and hypoxia. Cell Cycle. 8:3838–3847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Rzymski T, Milani M, Pike L, et al:
Regulation of autophagy by ATF4 in response to severe hypoxia.
Oncogene. 29:4424–4435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Schafranek L, Leclercq TM, White DL and
Hughes TP: Clarithromycin enhances dasatinib-induced cell death in
chronic myeloid leukemia cells, by inhibition of late stage
autophagy. Leuk Lymphoma. 54:198–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Carella AM, Beltrami G, Pica G, Carella A
and Catania G: Clarithromycin potentiates tyrosine kinase inhibitor
treatment in patients with resistant chronic myeloid leukemia. Leuk
Lymphoma. 53:1409–1411. 2012. View Article : Google Scholar
|
|
46.
|
Gay F, Rajkumar SV, Coleman M, et al:
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd)
versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed
myeloma. Am J Hematol. 85:664–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Niesvizky R, Jayabalan DS, Christos PJ, et
al: BiRD (Biaxin [clarithromycin]/Revlimid
[lenalidomide]/dexamethasone) combination therapy results in high
complete- and overall-response rates in treatment-naive symptomatic
multiple myeloma. Blood. 111:1101–1109. 2008.
|
|
48.
|
Mikasa K, Sawaki M, Kita E, et al:
Significant survival benefit to patients with advanced
non-small-cell lung cancer from treatment with clarithromycin.
Chemotherapy. 43:288–296. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Ohara T, Morishita T, Suzuki H, Masaoka T,
Ishii H and Hibi T: Antibiotics directly induce apoptosis in B cell
lymphoma cells derived from BALB/c mice. Anticancer Res.
24:3723–3730. 2004.PubMed/NCBI
|
|
50.
|
Wada T, Sata M, Sato J, et al:
Clarithromycin suppresses invasiveness of human lung adenocarcinoma
cells. Chemotherapy. 53:77–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Yatsunami J, Fukuno Y, Nagata M, et al:
Roxithromycin and clarithromycin, 14-membered ring macrolides,
potentiate the antitumor activity of cytotoxic agents against mouse
B16 melanoma cells. Cancer Lett. 147:17–24. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Hamada K, Kita E, Sawaki M, Mikasa K and
Narita N: Antitumor effect of erythromycin in mice. Chemotherapy.
41:59–69. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Yamamoto A, Tagawa Y, Yoshimori T,
Moriyama Y, Masaki R and Tashiro Y: Bafilomycin A1 prevents
maturation of autophagic vacuoles by inhibiting fusion between
autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E
cells. Cell Struct Funct. 23:33–42. 1998. View Article : Google Scholar
|
|
54.
|
Klionsky DJ, Elazar Z, Seglen PO and
Rubinsztein DC: Does bafilomycin A1 block the fusion of
autophagosomes with lysosomes? Autophagy. 4:849–950. 2008.
View Article : Google Scholar : PubMed/NCBI
|
